Health CarePharmaceuticals & Biotechnology
  • Price (USD)319.58
  • Today's Change0.000 / 0.00%
  • Shares traded1.07m
  • 1 Year change6.15%
  • Beta1.0663
Data delayed at least 15 minutes, as of Jan 24 2020 21:00 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

  • Revenue in USD (TTM)3.46bn
  • Net income in USD973.00m
  • Incorporated2000
  • Employees7.30k
  • Location
    Illumina Inc5200 Illumina WaySAN DIEGO 92122-4616United StatesUSA
  • Phone+1 (858) 202-4500
  • Fax+1 (858) 202-4766
  • Websitehttps://www.illumina.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Cognex Corporation749.14m179.98m9.87bn2.12k56.227.9648.4413.171.030.9644.277.250.55182.485.59352,703.4013.2617.5414.2719.0173.6175.8024.0329.656.90--0.0011.795.2521.25-20.7627.9422.6246.41
Avantor Inc5.99bn-484.50m10.69bn12.00k--7.9032.431.78-0.9077-0.962910.974.120.60265.916.23499,183.30-0.5694---0.6364--31.27---0.9449--
PerkinElmer, Inc.2.83bn232.50m11.09bn12.50k47.864.1025.383.912.082.1025.4224.370.4593.914.73226,762.103.764.514.445.2648.4846.978.209.260.97356.620.454814.6123.085.18-10.626.2019.060.00
Bio-Rad Laboratories, Inc.2.30bn327.66m11.10bn8.26k35.062.1624.034.8210.5512.1976.82171.410.33161.756.25278,944.104.723.035.043.4454.8154.6914.225.573.36--0.07890.005.981.43505.9732.412.82--
Allegion PLC2.84bn432.00m11.89bn11.00k28.0617.3823.084.194.564.7929.947.361.015.607.78257,900.0015.4611.4418.7514.5043.4843.0115.2411.351.3010.040.67519.5413.435.7126.8462.9919.44--
Waters Corporation2.41bn568.89m15.31bn7.20k29.67133.9222.696.368.018.1133.881.770.72842.934.84334,072.4017.2311.8820.4713.5958.4958.9523.6523.681.6340.210.92150.004.804.914.375.751.49--
Keysight Technologies Inc4.30bn590.00m19.41bn13.60k33.316.4321.614.513.093.2522.5616.020.69142.676.66316,397.109.487.2611.828.9558.8955.7213.7110.132.5011.760.37310.0010.967.97276.369.6411.38--
Mettler-Toledo International Inc.2.98bn553.14m19.97bn16.00k37.3945.5631.176.7021.9321.79118.3618.001.154.525.98186,412.9021.3018.4229.2925.7957.6856.7718.5515.630.949419.590.7280.007.734.2915.2411.0211.63--
AMETEK, Inc.5.13bn840.24m22.76bn18.20k27.224.6821.404.443.663.7122.3121.290.59155.386.59281,596.909.708.6311.0210.0934.6736.2516.3914.501.4813.550.33315.1612.696.1629.888.185.3318.47
Fortive Corp6.33bn574.30m25.83bn24.00k45.473.6126.924.081.697.6518.6621.300.4154.664.82263,895.804.229.715.3411.7251.0349.7910.1613.980.9556.060.45655.8112.101.596.890.93326.73--
Agilent Technologies Inc5.16bn1.07bn27.38bn16.30k26.285.7420.915.303.363.3616.2515.370.57393.576.05316,748.5011.908.3114.539.7554.4853.1720.7415.461.2123.980.336424.135.074.9923.3935.79-5.324.43
Emerson Electric Co.18.37bn2.21bn46.72bn88.00k21.555.6915.322.543.563.7229.6013.470.89875.726.12208,772.7010.909.6115.5514.2342.5542.5912.1312.460.8817.780.408861.305.540.710514.500.9364-1.822.65
Illumina, Inc.3.46bn973.00m46.98bn7.30k49.0710.5841.1713.596.516.5123.1330.200.49942.697.10473,698.6013.6913.2716.9516.5769.2668.9027.4122.766.15--0.2030.0021.1118.59-4.4546.2026.73--
Data as of Jan 24 2020. Currency figures normalised to Illumina Inc's reporting currency: US Dollar USD

Institutional shareholders

46.94%Per cent of shares held by top holders
HolderShares% Held
Baillie Gifford & Co.as of 31 Dec 201917.74m12.07%
The Vanguard Group, Inc.as of 30 Sep 201911.17m7.60%
Capital Research & Management Co. (Global Investors)as of 30 Sep 20197.91m5.38%
BlackRock Fund Advisorsas of 30 Sep 20197.87m5.35%
SSgA Funds Management, Inc.as of 30 Sep 20196.03m4.11%
Jennison Associates LLCas of 30 Sep 20194.84m3.29%
Edgewood Management LLCas of 30 Sep 20194.78m3.25%
Sands Capital Management LLCas of 30 Sep 20193.53m2.40%
Morgan Stanley Investment Management, Inc.as of 30 Sep 20192.81m1.92%
Geode Capital Management LLCas of 30 Sep 20192.32m1.58%
More ▼
Data from 30 Sep 2019 - 30 Sep 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.